Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.11
€0.04(1.75%)
At close: 4:00 PM EDT
€2.11
€0.04(1.75%)
Day’s Range― - ―
52-Week Range€2.03 - €5.42
Previous CloseN/A
Volume117.56K
Average Volume (3M)1.29M
Market Cap
€418.17M
Enterprise Value€589.53
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€152.15M
Bulls Say, Bears Say
Bulls Say
Lyme Vaccine Phase III EfficacyRobust Phase III efficacy (>70%) and planned regulatory filings via Pfizer represent a structural commercial opportunity. As the only late‑stage Lyme vaccine in decades, successful approvals would open large North American and European markets, creating durable revenue optionality beyond travel vaccines.
IXCHIQ (Chikungunya) Access And CampaignsLocal licensure and a >30k person Brazil pilot establish real‑world uptake and manufacturing/market access. Country‑level adoption and local production reduce export dependence and support sustainable commercial rollouts in endemic markets, diversifying revenue away from travel vaccines.
Restructuring And Cost Reduction ProgramA comprehensive program targeting large opex cuts is a structural lever to lower burn and improve operating leverage. If executed, permanent expense base reduction can extend runway and increase the chance that R&D and commercialization can proceed without repeated dilutive financings.
Bears Say
Elevated Leverage And Shrinking EquityHigh debt relative to a diminished equity base constrains financial flexibility and raises refinancing or dilution risks. With limited equity cushion, further losses or asset write‑downs could force equity raises under unfavorable terms, impairing long‑term strategic optionality and stakeholder returns.
Persistent Negative Cash GenerationSustained operating and free cash flow deficits increase dependency on external funding and limit reinvestment. Continued cash burn makes planned commercialization and late‑stage programs contingent on capital markets or partners, adding execution risk and potential for disruptive financing terms.
Revenue Decline, Margin Pressure & Manufacturing/regulatory RiskSharp revenue decline and compressed gross margins reflect weaker end‑market demand and one‑off manufacturing costs. Coupled with FDA observations limiting US production paths, these structural operational and regulatory constraints can depress margins, complicate supply continuity, and slow commercial recovery.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.03 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €418.17M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 13 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went up 1.897%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE (VLA) is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, with an emphasis on products addressing unmet medical needs. It operates in the biotechnology/pharmaceuticals sector and markets travel and endemic-disease vaccines, while also advancing a pipeline of vaccine candidates through clinical development and pursuing collaborations with public and private partners.